2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)

Bristol Myers Squibb offers a 4.2% dividend yield while facing scheduled patent expirations without clear replacement blockbusters, though the article cites its pipeline as a potential offset. Realty Income yields 6% and has raised its dividend annually for 31 years, but rising rates and bond yields are pressuring its cost of capital and near-term acquisition economics. The article presents both stocks as potential long-term income opportunities for investors willing to accept near-term headwinds.

Analysis

The article’s high-yield framing obscures two different underwriting questions: whether BMY can replace earnings exposed to exclusivity loss, and whether O can maintain attractive incremental returns as its funding costs reset. Neither yield alone establishes undervaluation. For BMY, the key second-order risk is not just lost sales: a weak replacement pipeline can constrain reinvestment capacity and cause investors to assign a lower multiple to future launches. Conversely, credible launch uptake or approvals could improve the durability of cash flows before the patent headwind fully rolls through. For O, higher rates pressure acquisition spreads and financing economics, but the duration of that pressure depends on debt maturities, fixed-versus-floating exposure, lease escalators, and property transaction pricing—details not established here. A broad rate rally could lift the shares quickly without resolving those fundamentals.

Near term, this reads as income-stock promotion rather than a fresh catalyst; avoid treating the yield premium as a signal to buy immediately. Over 1–3 months, track BMY’s product-level growth and guidance against anticipated exclusivity losses, and O’s financing-cost outlook and acquisition economics. Over 6–18 months, pipeline conversion is the BMY thesis; for O, refinancing and property repricing determine whether dividend growth remains economically supported. The contrarian point: the apparent opportunity may be a value trap if income investors focus on payout history while earnings or investment spreads deteriorate.

Key Decisions for Investors

• BMY: Watch rather than chase the yield. Consider a staged, modest long only after company disclosures provide a credible product-by-product bridge from exclusivity losses to replacement revenue. Falsify the thesis if guidance is reduced or key launches fail to show uptake; verify the timing and scale of those exposures before sizing.
• O: Make the entry conditional on rates and fundamentals, not the headline yield. Track Treasury yields alongside O’s debt maturity/fixed-rate profile, financing costs, and acquisition spreads; a sustained rise in funding costs without compensating rent or property economics would argue against adding.
• Avoid an O-versus-BMY pair: their principal risks are different, so the relative yield spread does not hedge the underlying exposures. If seeking income exposure now, keep sizing conservative and diversify across the relevant sectors rather than concentrating on these two names.
• Catalyst watch: distinguish a broad duration-driven bounce in O from improving property economics, and distinguish BMY pipeline announcements from measurable commercial contribution. Reassess only when filings, guidance, or operating data verify those changes.